Glenmark Asks Fed. Circ. To Nix Patent In $16M Abbott Win

Law360, Washington (March 08, 2013, 7:09 PM ET) -- Glenmark Pharmaceuticals Ltd. on Friday slammed Abbott Laboratories' blood pressure drug Tarka as a "commercial disaster" that never should have received patent protection because of thousands of similar treatment combinations, urging a Federal Circuit panel to nix the patent and the company's $16 million infringement win.

Although Abbott's counsel John Allcock touted Tarka as an example of “inventor insight,” plucking the specific ACE inhibitor-calcium antagonist combination out of thousands of possibilities, Glenmark maintained those same alternatives show Tarka's patent protection was completely inappropriate.

“This is a...
To view the full article, register now.